- And that’s a wrap 2023! Christmas with IR Department
- This is what the ASX and investors expect for gender diversity on your board
- 5 key lessons any company can take away from our foundational ESG report
- What small caps can take away from Amazon’s move to write emissions data into its supplier standards
- How Australian small caps are likely to be impacted by the new ISSB sustainability disclosure standards
And that’s a wrap 2023! Christmas with IR Department
2023 has been another exciting year for the team. In this blog post, the IR Department team provides their reflections on one interesting fact or lesson they learnt this year, and one favourite book/podcast (or TV series) recommendation.
IR Department expands with ESG practice and new team members
- New ESG practice bolsters consultancy’s client offering
- Appointment of Jack McLintock, Annabelle Dick and Anna Cvijetić expand IR Department’s investor and public relations expertise
IWD2023 interview series, Feature Five: Gertrude Biomedical CEO/Managing Director, Tara Karnezis
Tara Karnezis is the Chief Executive Officer and Managing Director of IR Department’s client, Gertrude Biomedical. Tara oversees Gertrude’s development of small molecule medicines that target cancer growth and spread.
We were grateful to her for giving us some time as part of our International Women's Day interview series, to discuss her perspective on this year’s theme, “Embracing Equity”.
IWD2023 interview series, Feature Four: HaemaLogiX Chair/CEO, Bryce Carmine
We were grateful for Bryce giving us some time, as part of our International Women's Day series, to share some insights and perspective on this year’s theme, “Embracing Equity”.
IWD2023 interview series, Feature Three: Pureprofile’s COO/CFO, Melinda Sheppard
Melinda Sheppard is the Chief Operating Officer and Chief Financial Officer with IR Department client, Pureprofile Limited (ASX: PPL). Together with CEO Martin Filz, Melinda has been instrumental in the turnaround of the Pureprofile business over the past few years.
We were grateful that she could spend some time with us as part of our International Women's Day series, to share some insights from her career and her perspective on this year’s theme, “Embracing Equity”.
IWD2023 – Mary Harney talks about the importance of mentoring and optimism
As part of International Women’s Day 2023, IR Department sat down with leaders across a range of industries to discuss their unique perspectives on the theme of “embracing equity”.
In this interview, we speak with Mary Harney (pictured), who is Non-Executive Director for our client, Race Oncology (ASX: RAC), and also Chair of both Oncology One and Microbio.
Mary has had a fascinating career history across health and agricultural sectors. A thoughtful, analytical and persuasive leader, Mary’s positive influence has seen prominent businesses and cultures transformed. A constant throughout her career has been the wealth of opportunity created for both women and men through mentoring and career championship.
IWD2023 interview series, Feature One: Servatus' Non-Executive Director Eilis Quinn
Recently Eilis took some time out to chat with our Communications Director, Cherie Hartley about International Women’s Day, her experiences and perspectives around this year’s theme, “Embracing Equity”.
Getting started with ESG – what’s it all about?
ESG (environmental, social, and governance) has become a key factor for investors when making investment decisions. As such, incorporating ESG into your investor relations approach is crucial for success.
Our latest blog post explores the benefits of ESG for companies, including attracting socially responsible investors, managing risks, building a positive brand reputation, and ensuring regulatory compliance. We also provide practical tips on how to integrate ESG into your investor relations approach. Read our blog post now and learn how to build a sustainable and responsible business that benefits all stakeholders.
BioSpectrum Asia’s 23 Life Science trends to watch in 2023
IR Department’s Managing Director honoured at Women in Finance Awards 2022
IR Department Managing Director Jane Lowe featured in CFO magazine
Podcast - interview with Peter Devine, CEO of Uniseed
Podcast - IR Department talks to Race Oncology's CSO Dr Daniel Tillett
Our Digital Content Producer, Paul Langley, talks with Race Oncology's CSO Dr Daniel Tillett, who explains how the recent clinical trials are evolving and what it means for the future. He gives a brief overview on the history of Race, their aspirations and milestones for development and eventual commercialisation of Zantrene.
Podcast - IR Department talks with AdAlta CEO & MD, Dr Tim Oldham
Our Communications Director, Cherie Hartley, talks with AdAlta's CEO & M.D. Dr Tim Oldham at this year's Bioshares Biotech Summit, who takes us inside the mind of a biotech company. He discussed the importance of focus for a platform company, explains why making decisions on a day-to-day basis is so crucial for risk reduction and why they're investing in supporting core strategies as well as their target product profile.
IRD Invest March 2022 - Openpay
IRD Invest March 2022 - Oventus
IRD Invest March 2022 - Pureprofile
Interview with Ben Fogarty, CEO (UK) XPON
We speak to Ben Fogarty, CEO (UK & Europe) from XPON Technologies Group (see video below) about what the future holds for them and the impact of the upcoming ‘Metaverse’.
A groundbreaking approach to cancer treatment
A number of breakthrough discoveries for Race Oncology's (ASX:RAC) drug Zantrene® over the past 18 months has seen the company evolve its strategy and clinical programs in order to maximise these opportunities. What does the future for Race look like?